{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:10:37Z","timestamp":1790701837108,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10637-020-00928-z","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T04:09:50Z","timestamp":1589429390000},"page":"1774-1783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment"],"prefix":"10.1007","volume":"38","author":[{"given":"Jean-Pierre","family":"Delord","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillem","family":"Argil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jer\u00f4me","family":"Fayette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Mesia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Dekervel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huai-Xiang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Tiedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian L.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"issue":"2","key":"928_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87\u2013108","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"928_CR2","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386\u20131422","journal-title":"Ann Oncol"},{"issue":"14","key":"928_CR3","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408\u20131417","journal-title":"N Engl J Med"},{"issue":"15","key":"928_CR4","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem E, K\u00f6hne CH, L\u00e1ng I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15):2011\u20132019","journal-title":"J Clin Oncol"},{"issue":"31","key":"928_CR5","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31):4697\u20134705","journal-title":"J Clin Oncol"},{"issue":"7","key":"928_CR6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","volume":"33","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Lenz HJ, K\u00f6hne CH et al (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33(7):692\u2013700","journal-title":"J Clin Oncol"},{"issue":"23","key":"928_CR7","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335\u20132342","journal-title":"N Engl J Med"},{"issue":"12","key":"928_CR8","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, D\u00edaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013\u20132019","journal-title":"J Clin Oncol"},{"issue":"1","key":"928_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/annonc\/mdu378","volume":"26","author":"MJ Sorich","year":"2015","unstructured":"Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS (2015) Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 26(1):13\u201321","journal-title":"Ann Oncol"},{"issue":"11","key":"928_CR10","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/nm.3388","volume":"19","author":"CR Chong","year":"2013","unstructured":"Chong CR, J\u00e4nne PA (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19(11):1389\u20131400","journal-title":"Nat Med"},{"issue":"5827","key":"928_CR11","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039\u20131043","journal-title":"Science"},{"issue":"52","key":"928_CR12","doi-asserted-by":"publisher","first-page":"20932","DOI":"10.1073\/pnas.0710370104","volume":"104","author":"J Bean","year":"2007","unstructured":"Bean J, Brennan C, Shih JY et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104(52):20932\u201320937","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"928_CR13","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1158\/2159-8290.CD-12-0558","volume":"3","author":"A Bardelli","year":"2013","unstructured":"Bardelli A, Corso S, Bertotti A et al (2013) Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 3(6):658\u2013673","journal-title":"Cancer Discov"},{"issue":"7","key":"928_CR14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nm.3870","volume":"21","author":"G Siravegna","year":"2015","unstructured":"Siravegna G, Mussolin B, Buscarino M et al (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21(7):795\u2013801","journal-title":"Nat Med"},{"issue":"7572","key":"928_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nature14969","volume":"526","author":"A Bertotti","year":"2015","unstructured":"Bertotti A, Papp E, Jones S et al (2015) The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 526(7572):263\u2013267","journal-title":"Nature"},{"issue":"34","key":"928_CR16","doi-asserted-by":"publisher","first-page":"54627","DOI":"10.18632\/oncotarget.10559","volume":"7","author":"K Raghav","year":"2016","unstructured":"Raghav K, Morris V, Tang C et al (2016) MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget 7(34):54627\u201354631","journal-title":"Oncotarget"},{"issue":"3","key":"928_CR17","first-page":"148","volume":"3","author":"H Mo","year":"2017","unstructured":"Mo H, Liu P (2017) Targeting MET in cancer therapy. Chronic Dis Transl Med 3(3):148\u2013153","journal-title":"Chronic Dis Transl Med"},{"issue":"6","key":"928_CR18","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1158\/0008-5472.CAN-13-2340-T","volume":"74","author":"P Luraghi","year":"2014","unstructured":"Luraghi P, Reato G, Cipriano E et al (2014) MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res 74(6):1857\u20131869","journal-title":"Cancer Res"},{"issue":"24","key":"928_CR19","doi-asserted-by":"publisher","first-page":"6751","DOI":"10.1158\/1078-0432.CCR-13-0423","volume":"19","author":"T Troiani","year":"2013","unstructured":"Troiani T, Martinelli E, Napolitano S et al (2013) Increased TGF-\u03b1 as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res 19(24):6751\u20136765","journal-title":"Clin Cancer Res"},{"issue":"22","key":"928_CR20","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-11-1157","volume":"17","author":"X Liu","year":"2011","unstructured":"Liu X, Wang Q, Yang G et al (2011) A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res 17(22):7127\u20137138","journal-title":"Clin Cancer Res"},{"issue":"10","key":"928_CR21","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1158\/1078-0432.CCR-18-2814","volume":"25","author":"S Baltschukat","year":"2019","unstructured":"Baltschukat S, Engstler BS, Huang A et al (2019) Capmatinib (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation. Clin Cancer Res 25(10):3164\u20133175","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"928_CR22","doi-asserted-by":"publisher","first-page":"9067","DOI":"10.1200\/JCO.2016.34.15_suppl.9067","volume":"34","author":"MH Schuler","year":"2016","unstructured":"Schuler MH, Berardi R, Lim W et al (2016) Phase (ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET + non-small cell lung cancer (NSCLC). J Clin Oncol 34(Suppl):9067 (Abstract 9067)","journal-title":"J Clin Oncol"},{"issue":"5 Suppl","key":"928_CR23","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1200\/jco.2014.32.15_suppl.2520","volume":"32","author":"Y Bang","year":"2014","unstructured":"Bang Y, Su W, Nam D et al (2014) Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors. J Clin Oncol 32(5 Suppl):2520 (Abstract 2520)","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"928_CR24","doi-asserted-by":"publisher","first-page":"9020","DOI":"10.1200\/JCO.2016.34.15_suppl.9020","volume":"34","author":"Y Wu","year":"2016","unstructured":"Wu Y, Kim D, Felip E et al (2016) Phase (ph) II safety and efficacy results of a single-arm ph ib\/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC). J Clin Oncol 34(Suppl):9020 (Abstract 9020)","journal-title":"J Clin Oncol"},{"issue":"10","key":"928_CR25","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9","volume":"17","author":"J Babb","year":"1998","unstructured":"Babb J, Rogatko A, Zacks S (1998) Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 17(10):1103\u20131120","journal-title":"Stat Med"},{"issue":"13","key":"928_CR26","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/sim.3230","volume":"27","author":"B Neuenschwander","year":"2008","unstructured":"Neuenschwander B, Branson M, Gsponer T (2008) Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 27(13):2420\u20132439","journal-title":"Stat Med"},{"issue":"1","key":"928_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1740774509356002","volume":"7","author":"B Neuenschwander","year":"2010","unstructured":"Neuenschwander B, Capkun-Niggli G, Branson M, Spiegelhalter DJ (2010) Summarizing historical information on controls in clinical trials. Clin Trials 7(1):5\u201318","journal-title":"Clin Trials"},{"issue":"31","key":"928_CR28","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","volume":"36","author":"YL Wu","year":"2018","unstructured":"Wu YL, Zhang L, Kim DW et al (2018) Phase Ib\/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. J Clin Oncol 36(31):3101\u20133109","journal-title":"J Clin Oncol"},{"issue":"11 Suppl","key":"928_CR29","doi-asserted-by":"publisher","first-page":"S257","DOI":"10.1016\/j.jtho.2016.09.018","volume":"11","author":"TM Bauer","year":"2016","unstructured":"Bauer TM, Schuler M, Berardi R et al (2016) MINI01.03: Phase (ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients with advanced cMET + NSCLC: topic: medical oncology. J Thorac Oncol 11(11 Suppl):S257\u2013S258 (Abstract)","journal-title":"J Thorac Oncol"},{"issue":"20","key":"928_CR30","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. Engl N J Med 357(20):2040\u20132048","journal-title":"Engl N J Med"},{"issue":"1","key":"928_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3816\/CCC.2006.n.01","volume":"6","author":"TB Gibson","year":"2006","unstructured":"Gibson TB, Ranganathan A, Grothey A (2006) Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6(1):29\u201331","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"928_CR32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/13543784.2018.1462336","volume":"27","author":"G Pasquini","year":"2018","unstructured":"Pasquini G, Giaccone G (2018) C-MET inhibitors for advanced non-small cell lung cancer. Expert Opin Investig Drugs 27(4):363\u2013375","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"928_CR33","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/humu.10175","volume":"21","author":"B Iacopetta","year":"2003","unstructured":"Iacopetta B (2003) TP53 mutation in colorectal cancer. Hum Mutat 21(3):271\u2013276","journal-title":"Hum Mutat"},{"issue":"7","key":"928_CR34","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S0959-8049(02)00040-0","volume":"38","author":"R Fodde","year":"2002","unstructured":"Fodde R (2002) The APC gene in colorectal cancer. Eur J Cancer 38(7):867\u2013871","journal-title":"Eur J Cancer"},{"issue":"4","key":"928_CR35","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/ijc.26467","volume":"131","author":"DP Modest","year":"2012","unstructured":"Modest DP, Jung A, Moosmann N et al (2012) The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. Int J Cancer 131(4):980\u2013986","journal-title":"Int J Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00928-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00928-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00928-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:49:33Z","timestamp":1678510173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00928-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["928"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00928-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,14]]},"assertion":[{"value":"7 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JP. Delord reports research funding from F. Hoffmann-La Roche, Novartis Pharmaceuticals Corporation, Genentech, Bristol-Myers Squibb, Debiopharm, and Merck Sharpe & Dohme; advisory board participation for Bristol-Myers Squibb, Genentech, Novartis Pharmaceuticals Corporation, Merck Sharpe & Dohme and Takeda; patent holding in the field of molecular signature of cancer drugs effects. G. Argil\u00e9s reports research funding, travel grants and advisory board participation for F. Hoffmann-La Roche, Bristol-Myers Squibb, Bayer, Servier, Amgen, Merck Serono and Menarini; honoraria to his institution from Bayer, Servier, Novartis Pharmaceuticals Corporation, Boehringer Ingelheim, Boston Pharmaceuticals, F. Hoffmann-La Roche, and Genentech. J. Fayette reports honoraria for consultancy or advisory role from AstraZeneca, Bristol-Myers Squibb, Merck Sharpe & Dohme, Merck Serono, Innate Pharma, and Biogen; research funding from AstraZeneca and Bristol-Myers Squibb; travel, accommodation, or expenses from Bristol-Myers Squibb, AstraZeneca and Merck Sharpe & Dohme. L. Wirth reports acting in an advisory role for Eisai, Loxo Oncology, Merck, Ayala, Cue Biopharma and Genentech. S. Kasper reports personal fees, research grants, and advisory board membership from Roche, Merck Serono, Lilly, Amgen, Servier, Sanofi Aventis, Bristol-Myers Squibb, and Merck Sharpe & Dohme. S. Siena reports acting in an advisory role for Amgen, Bayer, Bristol-Myers Squibb, Roche, Merck, Merck Sharpe & Dohme, Novartis Pharmaceuticals Corporation, and Sanofi. R. Mesia reports an advisory role for Merck, Bristol-Myers Squibb, Merck Sharpe & Dohme, AstraZeneca, Roche, and Nanobiotix; speaker bureaus for Merck, Bristol-Myers Squibb, and Merck Sharpe & Dohme. A. Cervantes reports research grants to his institution form Novartis Pharmaceuticals Corporation to develop clinical trials on investigational compounds. J. Dekervel reports speaker fees, consulting fees or travel grants from Amgen, Bayer, Ipsen, Novartis Pharmaceuticals Corporation, Merck and Servier. L. Siu reports research funding for her institution from Novartis Pharmaceuticals Corporation for the conduct of this study. A. Myers, Y. Sun, H.-X. Hao, R. Tiedt, S. Vicente, and S. Zhao are all employed by Novartis Pharmaceuticals Corporation. R. Berardi declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}